Vesicare Ls is owned by Astellas.
Vesicare Ls contains Solifenacin Succinate.
Vesicare Ls has a total of 1 drug patent out of which 0 drug patents have expired.
Vesicare Ls was authorised for market use on 26 May, 2020.
Vesicare Ls is available in suspension;oral dosage forms.
The generics of Vesicare Ls are possible to be released after 18 May, 2031.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9918970||ASTELLAS||Pharmaceutical composition comprising solifenacin|| |
(8 years from now)
|New Product (NP)||May 26, 2023|
|Pediatric Exclusivity (PED)||Nov 26, 2023|
Market Authorisation Date: 26 May, 2020
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic